The China Newsweek has recently reported on the infections of the “superbug”—Candida auris (C. auris) in China. According to Liao Wanqing, an academician of the Chinese Academy of Engineering and professor in the Dermatology Department of Changzheng Hospital, Second Military Medical University, “18 cases of clinical infection with the superbug have so far been confirmed in China.” The infections of the superbug have been much concerned by the public due to the high fatality rate (more than 60%) thereof. The U.S. Centers for Disease Control and Prevention (CDC) has listed C. auris as an imminent threat, and the “superbug” control situations are also very severe in the UK, Japan, and India, etc. And as there is still no specific drug, more than 50% “superbug” infected people will die in 90 days. Such severe situations have raised very exigent requirements to the pharmaceutical practitioners.
